Ciraparantag (trifluoroacetate

一种抗凝逆转剂；在无细胞测定中，与依多沙班、利伐沙班、因子Xa、因子IX、凝血酶、抗凝血酶和纤维蛋白原相比，选择性地与未分级肝素、依诺肝素和因子IXa结合（Kds分别为28、17和35µM），与依诺肝素-抗凝血酶复合物和磺达肝癸钠结合较弱（Kds分别为690和9,600µM）；在浓度为200µg/ml时，可防止依多沙班引起的分离人全血中纤维蛋白直径减小；在大鼠中，可减少依多沙班、达比加群、阿哌沙班、利伐沙班、未分级肝素或依诺肝素刺激的尾部横断引起的失血量增加。An anticoagulant reversal agent; selectively binds to unfractionated heparin, enoxaparin, and Factor IXa (Kds = 28, 17, and 35 µM, respectively) over edoxaban, rivaroxaban, Factor Xa, Factor IX, thrombin, antithrombin, and fibrinogen, and only weakly binds to an enoxaparin-antithrombin complex and fondaparinux (Kds = 690 and 9,600 µM, respectively), in cell-free assays; prevents edoxaban-induced decreases in fibrin diameter in isolated human whole blood at 200 µg/ml; reduces edoxaban-, dabigatran-, apixaban-, rivaroxaban-, unfractionated heparin-, or enoxaparin-stimulated increases in tail transection-induced blood loss in rats.分子式C22H48N12O2 • XCF3COOH分子量512.7N=C(N)NCCC[C@H](N)C(NCCCN1CCN(CC1)CCCNC([C@@H](N)CCCNC(N)=N)=O)=O.OC(C(F)(F)F)=O